Shanghai Henlius Biotech's (HKG:2696) new drug application for its denosumab HLX1 biosimilar was accepted by China's National Medical Products Administration.
The indications covered in the application are bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of the bone, according to a Friday bourse filing.